A new Phase 3 trial has reported a significant improvement in recurrence-free survival for patients with non-muscle-invasive bladder cancer (NMIBC), raising the possibility of a new treatment option for patients who remain at risk of recurrence even after their tumors have been surgically removed.
On November 16, 2026, CG Oncology announced that its investigational oncolytic immunotherapy, cretostimogene grenadenorepvec, reduced the risk of bladder cancer recurrence by 68% compared with surveillance alone in the Phase 3 PIVOT-006 trial.
The study met its primary endpoint of recurrence-free survival (RFS), demonstrating a hazard ratio of 0.32 (95% CI, 0.23–0.45; p<0.0001) after a median follow-up of 17 months.
Importantly, no Grade 3 or higher treatment-related adverse events or treatment-related treatment discontinuations were reported.
The results could have implications for the management of intermediate-risk and selected high-grade Ta NMIBC, particularly in a setting where preventing recurrence remains a central clinical challenge.
Why Does Recurrence Remain a Major Challenge in Bladder Cancer?
For many patients with non-muscle-invasive bladder cancer, successful surgical removal of the tumor does not necessarily mean the end of treatment or follow-up.
Although NMIBC has not invaded the muscular layer of the bladder wall, the disease is characterized by a substantial risk of recurrence. Patients often require repeated cystoscopies, additional transurethral resections, and sometimes further intravesical treatments.
These repeated procedures can impose a considerable burden on patients and healthcare systems, even when the disease does not progress to muscle-invasive cancer.
Transurethral resection of bladder tumor (TURBT) remains a cornerstone of initial management. However, the decision to administer adjuvant intravesical therapy depends on the patient’s risk category, tumor characteristics, and previous treatment history.
For patients with intermediate-risk NMIBC, the challenge is particularly nuanced: clinicians must balance the benefits of reducing recurrence against treatment toxicity, inconvenience, and the possibility of overtreatment.
According to CG Oncology, approximately 50,000 patients in the United States fall within the population addressed by PIVOT-006, for which the company states that no adjuvant treatment currently has specific FDA approval.
The PIVOT-006 results introduce the possibility of a new post-resection approach designed to reduce recurrence without the toxicity associated with more intensive systemic treatment.
PIVOT-006: A Randomized Phase 3 Trial Evaluating Cretostimogene After Surgery
The Phase 3 PIVOT-006 trial (NCT06111235) enrolled 367 patients across approximately 90 clinical sites in the United States and Canada, making it one of the larger randomized studies conducted in this NMIBC population.
The trial evaluated adjuvant intravesical cretostimogene grenadenorepvec compared with surveillance following complete tumor resection.
Patients were randomized to receive either cretostimogene after TURBT or surveillance alone.
The study included several clinical presentations classified under intermediate-risk NMIBC in the American Urological Association/Society of Urologic Oncology guidelines at the time of trial initiation, including recurrent low-grade Ta tumors within 12 months, solitary low-grade Ta tumors larger than 3 cm, multifocal low-grade Ta disease, low-grade T1 disease, and solitary high-grade Ta tumors measuring 3 cm or less.
Patients assigned to cretostimogene received an induction course followed by maintenance treatment at scheduled intervals, provided they remained free of recurrence. Those assigned to the comparator arm underwent surveillance after tumor resection.
By comparing cretostimogene with surveillance, the investigators sought to determine whether an intravesical oncolytic immunotherapy could provide an additional benefit after complete surgical removal of visible disease.
Phase 3 Results: A 68% Reduction in Bladder Cancer Recurrence Risk
At the October 26, 2026, data cutoff, with a median follow-up of 17 months, PIVOT-006 achieved its primary endpoint of recurrence-free survival.
Patients receiving cretostimogene experienced a 68% relative reduction in the hazard of recurrence compared with those assigned to surveillance.
The reported hazard ratio was 0.32, with a 95% confidence interval of 0.23–0.45 and p<0.0001, indicating a statistically significant difference between the two treatment strategies.
The company also reported that the recurrence-free survival benefit was observed in patients with both high-grade and low-grade disease, suggesting that the treatment effect may extend across different clinical presentations represented in the trial.
However, the announcement provides topline findings rather than a complete analysis of the study.
Absolute recurrence-free survival rates, median recurrence-free survival, detailed subgroup estimates, and comprehensive safety results were not included in the initial release.
These additional data will be important for understanding the magnitude and durability of benefit, particularly when considering treatment decisions for patients with different baseline risks.
Another important consideration is that the comparator was surveillance rather than an active intravesical treatment. Consequently, the results establish a benefit over surveillance but do not determine whether cretostimogene is superior to other intravesical treatment strategies used in clinical practice.
Safety Findings: No Grade 3 or Higher Treatment-Related Adverse Events
Beyond efficacy, tolerability represents an important consideration for patients with NMIBC, who may require repeated courses of intravesical treatment.
According to CG Oncology, cretostimogene was generally well tolerated in PIVOT-006, with a safety profile consistent with observations from previous studies.
The company reported no Grade 3 or higher treatment-related adverse events and no discontinuations attributed to treatment-related toxicity.
These findings are encouraging for an adjuvant treatment intended for patients whose tumors have already been completely resected.
Nevertheless, detailed information about lower-grade adverse events and their frequency will be necessary to establish the overall treatment burden.
Vijay Kasturi, MD, Chief Medical Officer of CG Oncology, emphasized the importance of preventing recurrence:
“For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden.”
How Does Cretostimogene Work?
Cretostimogene grenadenorepvec is an investigational intravesical oncolytic immunotherapy based on a genetically modified adenovirus.
Unlike systemic immunotherapies that circulate throughout the body, cretostimogene is delivered directly into the bladder, where it is designed to act against cancer cells and stimulate a local antitumor immune response.
Its proposed mechanism involves two complementary processes.
First, the modified adenovirus is designed to preferentially replicate in tumor cells with alterations in the retinoblastoma (Rb)-E2F signaling pathway. Viral replication leads to the destruction of infected cancer cells, a process known as oncolysis.
Second, the virus carries the gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine intended to recruit and activate immune cells and promote antitumor immunity.
This combination of direct tumor-cell destruction and immune activation distinguishes cretostimogene from conventional intravesical chemotherapy.
The therapeutic concept is particularly relevant in NMIBC because the bladder permits direct administration of treatment to the affected organ.
However, the clinical relevance of the proposed immune mechanisms remains dependent on the efficacy and safety demonstrated in controlled trials.
Beyond PIVOT-006: Cretostimogene’s Expanding Clinical Development Program
The PIVOT-006 results represent another development within CG Oncology’s broader clinical program evaluating cretostimogene across different NMIBC populations.
The drug is also being investigated in high-risk, bacillus Calmette-Guérin (BCG)-unresponsive NMIBC, where treatment options remain limited and radical cystectomy may be recommended for appropriately selected patients.
The Phase 3 BOND-003 trial (NCT04452591) evaluated cretostimogene monotherapy in patients with high-risk BCG-unresponsive NMIBC.
Results from Cohort C, published in The Lancet Oncology in 2026, demonstrated a complete response rate of 75.5% at any time among patients with carcinoma in situ (CIS), with or without concomitant papillary disease.
Among responders, the estimated duration-of-response rates were 64.2% at 12 months and 60.1% at 24 months.
While BOND-003 focused on patients with high-risk BCG-unresponsive disease, PIVOT-006 examined a different clinical setting: patients with intermediate-risk or selected high-grade Ta disease following complete tumor resection.
The distinction is important because the two trials address different clinical questions and use different efficacy endpoints.
Together, the studies contribute to a growing body of evidence evaluating cretostimogene across multiple stages of non-muscle-invasive bladder cancer management.
FDA Plans: Two Regulatory Submissions Expected in 2027
Following the positive PIVOT-006 findings, CG Oncology outlined plans for two regulatory submissions to the US Food and Drug Administration (FDA).
The company expects to submit a biologics license application (BLA) seeking approval of cretostimogene for intermediate-risk and high-grade Ta NMIBC during the second quarter of 2027, supported by PIVOT-006.
At the same time, the company is expanding the scope of its initial BLA submission for BCG-unresponsive NMIBC.
Originally focused on patients with CIS, with or without papillary tumors, the submission is now expected to include patients with high-grade papillary-only disease following feedback from the FDA.
CG Oncology anticipates completing this broader submission before the end of March 2027.
The company also reported that manufacturing activities required to support both regulatory filings have been completed.
Cretostimogene has previously received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC. However, it remains investigational, and its safety and efficacy have not yet been established by the FDA.
What Comes Next for PIVOT-006?
The next major milestone will be the presentation of detailed PIVOT-006 results at the Society of Urologic Oncology (SUO) Annual Meeting on December 2, 2026, where the findings are scheduled for a late-breaking podium presentation.
The presentation is expected to provide greater clarity about recurrence-free survival outcomes, including the absolute magnitude of benefit, subgroup results, and safety characteristics.
Longer follow-up will also be important in determining whether the reduction in recurrence translates into sustained clinical benefit.
For clinicians, key questions remain: Which patients are most likely to benefit from post-resection cretostimogene? How should it be positioned relative to existing intravesical approaches? And can the improvement in recurrence-free survival meaningfully reduce the need for repeated surgical interventions?
The current results cannot answer all of these questions.
Nevertheless, PIVOT-006 provides randomized Phase 3 evidence that an intravesical oncolytic immunotherapy can substantially reduce recurrence risk compared with surveillance after complete tumor resection.
For patients with NMIBC, where treatment frequently extends beyond the initial surgery and repeated recurrences can significantly affect quality of life, preventing another tumor may be an important outcome in itself.
Whether cretostimogene ultimately becomes part of routine post-resection care will depend on the full clinical dataset, regulatory review, and its place within established bladder cancer treatment pathways.
Read further on OncoDaily: FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer

